CiplaQ4 FY24

Cipla Q4 FY24 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹1,388P/E: 36.1Market Cap: ₹1.1L CrSector: Pharmaceuticals & Biotechnology

Management growth scorecard

Revenue

Category 3

Margin

Category 1

Fundraise

N/A

Order

N/A

Capex

Yes

2 of 3 growth signals are positive.

Full analysis

Revenue guidance

Category 3
  • Cipla does not provide specific revenue growth guidance but aims to grow faster than the market in key markets like India, U.S., and South Africa.
  • One-India business posted 10% growth in FY24, driven by branded prescription and trade generics.
  • Emerging markets are expected to show respectable double-digit growth as economic conditions have bottomed out and the European pipeline unlocks.
  • Sustained growth in North America, backed by commercial execution of existing portfolio and new launches.
  • Growth drivers include organic investments in R&D, peptides, complex generics (12 assets filed), and new product launches including peptides and 505(b)(2) complex ANDAs.
  • Trade Generics segment expected to recover after short-term transition effects.
  • Focus on expanding chronic and respiratory therapy portfolios and increasing market share (e.g., Albuterol market share increase from 12%-15.5%).
  • Capital investments planned at INR1,500 crores for manufacturing and capability enhancement.
  • EBITDA margins targeted at 24.5%-25.5%, reflecting improved cost efficiencies.

See what Cipla management said on margin guidance — free account, 30 seconds.

Fundraise plans

  • There is no specific mention of any current or future fundraising plans through debt or equity in the provided document excerpts.
  • Cipla reported a healthy cash position with gross debt of INR559 crores and cash equivalents at INR8,267 crores as of the date.
  • The company noted plans for capital allocation focused on large growth opportunities and M&A but did not mention raising new capital.
  • Investments will be made internally, including INR1,500 crores capital investments towards capacity and capability enhancements.
  • Dividend payout has been increased, indicating utilization of free cash flow for shareholder returns and growth investments rather than external fundraising.
  • Cipla stated active pursuit of inorganic partnerships/acquisitions likely funded from internal resources.

See what Cipla management said on order book — free account, 30 seconds.

Capex plans

Yes
  • Cipla plans to deploy INR 1,500 crores in capital investments to enhance manufacturing capability and sustainability (Page 6).
  • Capital investments for the year FY24 stood at INR 1,315 crores, with 70% directed towards growth and capacity improvements, and the rest toward maintenance and sustainability (Page 5).
  • The company is investing in new facilities, such as a Dry Powder Inhaler (DPI) plant, with equipment qualification and feasibility batches underway (Page 12).
  • Cipla is focusing on investments in biosimilars and advanced science areas like CAR-T and Stempeutics for long-term growth (Page 11).
  • Ashish Adukia mentioned potential large acquisitions in India for filling white spaces and smaller, focused product acquisitions in the U.S., primarily for differentiated products with longer market life (Page 7).
  • Capital allocation strategy includes stepped-up dividends and active pursuit of large M&A growth opportunities (Page 12).

Track Cipla — get its next earnings analysis in your feed

How does Cipla rank vs peers in Pharmaceuticals & Biotechnology?

Pro feature
ThisCipla
Rev 3Mar 1

How does Cipla rank in Pharmaceuticals & Biotechnology?

Compare Cipla against every Pharmaceuticals & Biotechnology company (Q4 FY24) on revenue, margins and earnings-call signals.

View Pharmaceuticals & Biotechnology leaderboard →

Others in Pharmaceuticals & Biotechnology this season

  • Lasa Supergeneri (Q2 FY27)

    306.11 Lakhs in Q2 Sept 30, 2025 (over 99% decline YoY). Key results statement takeaways from Lasa Supergenerics Ltd's Q2 FY27 results statement — and how it ra

  • Themis Medicare (Q2 FY27)

    Q2 FY27 net revenue: ₹89.74 crore, up 15.1% year-on-year from ₹77.99 crore in Q2 FY26 (Page 8). Key investor presentation takeaways from Themis Medicare Ltd's Q

  • Panacea Biotec (Q2 FY27)

    September 30, 2026: ₹18,967 Lakh . Key results statement takeaways from Panacea Biotec Ltd's Q2 FY27 results statement — and how it ranks against sector peers.

  • Biofil Chemicals (Q2 FY27)

    Quarterly Revenue (Q2 ended 30/09/2026):** ₹166.87 Lakhs (Pharma Unit), ₹0.00 Lakhs (Chemicals Division); Total Gross Turnover ₹166.87 Lakhs. Key results statem

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →